A COMPARATIVE ASSESSMENT OF PHARMACOLOGICALLY ACTIVE PRINCIPLES AND ANTIOXIDANT ACTIVITY OF COMMONLY OCCURRING MUCUNA SPS. IN INDIA

The genus Mucuna (Fabaceae) includes about 150 species and almost all the species are reported to contain L-3,4-dihydroxy phenylalanine (L-Dopa), a non-protein amino acid that acts as precursor for the neurotransmitter dopamine, used in the treatment of Parkinsons disease. The present study was aimed to assess the pharmacologically active principles and antioxidant activities of Mucuna pruriens (L.) DC., Mucuna bracteata DC., Mucuna cochinchinensis (Lour.) A. Chev. black seeds sp. and Mucuna cochinchinensis (Lour.) A. Chev. white seeds sp. The aqueous extract of plant material was subjected to assess the pharmacologically active principles by using L-dopa quantification, determination of protein and flavonoids, total phenolic content, Inhibition of DPPH radical and Reducing power/Ferric reducing antioxidant potential (FRAP) assays. The results obtained showed that, Mucuna cochinchinensis black seeds sp. has highest protein, total phenolic content, L-dopa content and DPPH radical scavenging activity. Mucuna bracteata seeds showed highest flavonoid content whereas, in FRAP assay Mucuna pruriens extract showed highest potential to reduce the ferric ions. It can be concluded from this study that, L-DOPA possesses antioxidant activity which was supported by in-vitro antioxidant assays. This indicates that the antioxidant activity of the aqueous extracts of all the Mucuna sps. may be due to the presence of L-Dopa content in its seed

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

DESIGN OF SUSPENSION SYSTEM OF ELECTRIC SOLAR VEHICLE

Suspension systems don't tend to get much publicity, but they're probably the most crucial factor&nbsp;in the day-to-day enjoyment of your car. Like most other components on a vehicle, manufacturers have taken many different approaches .when&nbsp; it comes to suspension design.Luxury cars are engineered for a comfortable ride, while sports cars need to corner at high speed.&nbsp;Trucks, on the other hand, need to carry heavy loads and may travel off the pavement. &nbsp